Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / LRIG3



This biomarker is also known as:
  • LIG-3,
  • leucine-rich repeats and immunoglobulin-like domains protein 3,
  • leucine-rich repeats and immunoglobulin-like domains 3,
  • LIRG3,
  • FLJ90440,
  • KIAA3016,
  • LIG3,

View in BioMuta


The LRIG3 protein is a widely expressed type I membrane protein. It contains three Ig-like C2-type (immunoglobulin-like) domains, 15 LRR (leucine-rich) repeats, 1 LRRCT domain, and 1 LRRNT domain.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


Decreased expression of LRIG3 protein in glioblastoma cell lines resulted in increased proliferation and invasion, decreased apoptosis, and increased EGFR expression, leading to the hypothesis that LRIG is a tumor suppressor. A decreased level of LRIG was also seen in the serum of lung cancer patients compared to controls in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

LRIG3 is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.